(BAYN) Bayer NA - Ratings and Ratios
Pharmaceuticals, Consumer Health, Crop Protection, Seeds, Digital Agriculture
EPS (Earnings per Share)
Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 39.6% |
| Value at Risk 5%th | 57.6% |
| Relative Tail Risk | -11.48% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.40 |
| Alpha | 59.64 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.473 |
| Beta | 0.009 |
| Beta Downside | 0.071 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.35% |
| Mean DD | 42.06% |
| Median DD | 52.74% |
Description: BAYN Bayer NA October 14, 2025
Bayer Aktiengesellschaft (XETRA:BAYN) is a global life-science conglomerate organized into three core segments: Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division focuses on prescription medicines for cardiology, womens health, oncology, hematology, and ophthalmology, and also supplies diagnostic imaging agents and emerging cell- and gene-therapy platforms.
The Consumer Health unit sells over-the-counter (OTC) products ranging from pain relievers and cardiovascular-risk prevention items to nutraceuticals, skincare, allergy, and cold-and-cough remedies. Distribution channels include pharmacies, supermarkets, online retailers, and direct-to-consumer platforms.
Crop Science provides chemical and biological crop-protection chemicals, seed traits, digital farming solutions, and related services. The segment also handles seed breeding, propagation, and processing, and it markets directly to farmers as well as through agricultural distributors.
Key recent metrics (FY 2023) show total revenue of €48.3 billion, with Pharmaceuticals contributing roughly 45 % of sales, Consumer Health about 12 %, and Crop Science the remaining 43 %. R&D expenditure stayed near €6 billion, reflecting continued investment in oncology pipelines (e.g., Xofigo) and gene-therapy platforms. EBIT margin hovered around 12 %, pressured by legacy litigation costs and volatile commodity prices affecting Crop Science.
Sector-level drivers that materially affect Bayer’s outlook include: (1) an aging global population driving higher demand for chronic-disease drugs; (2) tightening environmental regulations and a shift toward sustainable agriculture, which boost demand for biological crop-protection products and digital farming tools; and (3) macro-economic exposure to commodity price cycles that can erode Crop Science margins during periods of high input costs.
Given these dynamics, analysts should monitor the rollout speed of Bayer’s next-generation oncology candidates and the adoption rate of its digital agronomy platform, as both are high-impact levers for future earnings growth.
For a deeper, data-driven assessment of Bayer’s valuation relative to its peers, you might find ValueRay’s interactive analytics useful.
BAYN Stock Overview
| Market Cap in USD | 30,516m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | |
| Return 12m vs S&P 500 | 35.9% |
| Analyst Rating | - |
BAYN Dividends
| Metric | Value |
|---|---|
| Dividend Yield | 0.36% |
| Yield on Cost 5y | 0.25% |
| Yield CAGR 5y | -55.48% |
| Payout Consistency | 87.5% |
| Payout Ratio | 2.1% |
BAYN Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | -12.67% |
| CAGR/Max DD Calmar Ratio | -0.19 |
| CAGR/Mean DD Pain Ratio | -0.30 |
| Current Volume | 3641.2k |
| Average Volume | 1658.6k |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-198.0m TTM) > 0 and > 6% of Revenue (6% = 2.75b TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA -0.35pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 8.56% (prev 17.29%; Δ -8.74pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 6.72b > Net Income -198.0m (YES >=105%, WARN >=100%) |
| Net Debt (34.62b) to EBITDA (5.50b) ratio: 6.30 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.14 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (982.4m) change vs 12m ago 0.00% (target <= -2.0% for YES) |
| Gross Margin 56.35% (prev 57.14%; Δ -0.79pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 43.44% (prev 43.70%; Δ -0.26pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.25 (EBITDA TTM 5.50b / Interest Expense TTM 1.83b) >= 6 (WARN >= 3) |
Altman Z'' 1.15
| (A) 0.04 = (Total Current Assets 32.88b - Total Current Liabilities 28.96b) / Total Assets 104.21b |
| (B) 0.09 = Retained Earnings (Balance) 9.87b / Total Assets 104.21b |
| (C) 0.02 = EBIT TTM 2.28b / Avg Total Assets 105.58b |
| (D) 0.43 = Book Value of Equity 31.91b / Total Liabilities 74.51b |
| Total Rating: 1.15 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 49.19
| 1. Piotroski 2.0pt |
| 2. FCF Yield 6.41% |
| 3. FCF Margin 8.58% |
| 4. Debt/Equity 1.38 |
| 5. Debt/Ebitda 6.30 |
| 6. ROIC - WACC (= 1.29)% |
| 7. RoE -0.64% |
| 8. Rev. Trend -34.88% |
| 9. EPS Trend -23.32% |
What is the price of BAYN shares?
Over the past week, the price has changed by +12.64%, over one month by +11.66%, over three months by +9.70% and over the past year by +55.44%.
Is BAYN a buy, sell or hold?
What are the forecasts/targets for the BAYN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 29.1 | -5.8% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 31.8 | 3.1% |
BAYN Fundamental Data Overview November 22, 2025
Market Cap EUR = 26.51b (26.51b EUR * 1.0 EUR.EUR)
P/E Forward = 5.1706
P/S = 0.578
P/B = 0.8975
P/EG = 4.7193
Beta = 0.833
Revenue TTM = 45.87b EUR
EBIT TTM = 2.28b EUR
EBITDA TTM = 5.50b EUR
Long Term Debt = 34.55b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 5.31b EUR (from shortTermDebt, last fiscal year)
Debt = 40.81b EUR (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 34.62b EUR (from netDebt column, last fiscal year)
Enterprise Value = 61.42b EUR (26.51b + Debt 40.81b - CCE 5.90b)
Interest Coverage Ratio = 1.25 (Ebit TTM 2.28b / Interest Expense TTM 1.83b)
FCF Yield = 6.41% (FCF TTM 3.94b / Enterprise Value 61.42b)
FCF Margin = 8.58% (FCF TTM 3.94b / Revenue TTM 45.87b)
Net Margin = -0.43% (Net Income TTM -198.0m / Revenue TTM 45.87b)
Gross Margin = 56.35% ((Revenue TTM 45.87b - Cost of Revenue TTM 20.02b) / Revenue TTM)
Gross Margin QoQ = 55.41% (prev 59.36%)
Tobins Q-Ratio = 0.59 (Enterprise Value 61.42b / Total Assets 104.21b)
Interest Expense / Debt = 1.87% (Interest Expense 762.0m / Debt 40.81b)
Taxrate = 17.40% (-202.0m / -1.16b)
NOPAT = 1.88b (EBIT 2.28b * (1 - 17.40%))
Current Ratio = 1.14 (Total Current Assets 32.88b / Total Current Liabilities 28.96b)
Debt / Equity = 1.38 (Debt 40.81b / totalStockholderEquity, last quarter 29.58b)
Debt / EBITDA = 6.30 (Net Debt 34.62b / EBITDA 5.50b)
Debt / FCF = 8.79 (Net Debt 34.62b / FCF TTM 3.94b)
Total Stockholder Equity = 31.08b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.19% (Net Income -198.0m / Total Assets 104.21b)
RoE = -0.64% (Net Income TTM -198.0m / Total Stockholder Equity 31.08b)
RoCE = 3.48% (EBIT 2.28b / Capital Employed (Equity 31.08b + L.T.Debt 34.55b))
RoIC = 4.60% (NOPAT 1.88b / Invested Capital 40.94b)
WACC = 3.32% (E(26.51b)/V(67.32b) * Re(6.05%) + D(40.81b)/V(67.32b) * Rd(1.87%) * (1-Tc(0.17)))
Discount Rate = 6.05% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 72.96% ; FCFE base≈4.13b ; Y1≈3.04b ; Y5≈1.75b
Fair Price DCF = 33.86 (DCF Value 33.27b / Shares Outstanding 982.4m; 5y FCF grow -31.08% → 3.0% )
EPS Correlation: -23.32 | EPS CAGR: -26.91% | SUE: 0.82 | # QB: 0
Revenue Correlation: -34.88 | Revenue CAGR: -7.58% | SUE: -0.21 | # QB: 0